A new test for cervical cancer was found to detect all of the cancers in a randomised clinical screening trial of 15,744 women, outperforming both the current Pap smear and human papillomavirus (HPV) test at a reduced cost, according to a study led by Queen Mary University of London.
The study, published in the International Journal of Cancer, compared a new ‘epigenetics-based’ cervical cancer test with Pap smear and HPV tests, and investigated how well it predicted the development of cervical cancer up to five years in advance in a large study of women aged 25-65 in Canada.
As opposed to checking for patterns in the DNA genetic code itself that are indicative of the HPV virus, the new test looks at the naturally-occurring chemical markers that appear on top of the DNA, making up its ‘epigenetic profile’.
‘An enormous development’
Lead researcher Professor Attila Lorincz from Queen Mary’s Wolfson Institute of Preventive Medicine who also helped develop the world’s first test for HPV in 1988, said: “This is an enormous development. We’re not only astounded by how well this test detects cervical cancer, but it is the first time that anyone has proven the key role of epigenetics in the development of a major solid cancer using data from patients in the clinic. Epigenetic changes are what this cervical cancer test picks up and is exactly why it works so well.
“In contrast to what most researchers and clinicians are saying, we are seeing more and more evidence that it is in fact epigenetics, and not DNA mutations, that drives a whole range of early cancers, including cervical, anal, oropharyngeal, colon, and prostate.”
Screening to prevent cervical cancer is typically done through the Pap smear, which involves the collection, staining and microscopic examination of cells from the cervix. Unfortunately, the Pap smear can detect only around 50 per cent of cervical pre-cancers.
A much more accurate cervical screening method involves testing for the presence of DNA from the human papillomavirus (HPV) – the primary but indirect cause of cervical cancer. There are estimated to be around 10 million women in the UK who are infected by HPV.
However, the HPV test only identifies whether or not women are infected with a cancer-causing HPV, but not their actual risks of cancer, which remain quite low. This causes unnecessary worry for the majority of HPV-infected women who receive a positive result but will eventually clear the virus and not develop the disease.
Predicting a person’s risk of cervical cancer
The new test was significantly better than either the Pap smear or HPV test. It detected 100 per cent of the eight invasive cervical cancers that developed in the 15,744 women during the trial. In comparison, the Pap smear only detected 25 per cent of the cancers, and the HPV test detected 50 per cent.
The study also looked more closely at a subset of 257 HPV-positive women which were representatively selected from the large study. The new test detected 93 per cent of pre-cancerous lesions in those women, compared to 86 per cent detected using a combination of the Pap smear and HPV test, and 61 per cent detected using the Pap smear on its own.
Reducing the number of screening appointments needed
Professor Lorincz added: “This really is a huge advance in how to deal with HPV-infected women and men, numbering in the billions worldwide, and it is going to revolutionise screening.
“We were surprised by how well this new test can detect and predict early cervical cancers years in advance, with 100 per cent of cancers detected, including adenocarcinomas, which is a type of cervical cancer that is very difficult to detect. The new test is much better than anything offered in the UK at present but could take at least five years to be established.”
The authors say that using this test in the clinic would reduce the number of visits to the doctor and screening appointments, as high-grade disease would be detected from the start. They also say that if it was fully implemented, it would be cheaper than the Pap smear.
The Latest on: Cervical cancer
via Google News
The Latest on: Cervical cancer
- Ministry vaccinates 280,000 girls against cervical canceron November 14, 2019 at 1:00 pm
HPV, which is sexually-transmitted, has been found to be the major cause of cervical cancer. The delay in the roll-out in the rest of the counties among them Garissa, Mandera and Turkana has been ...
- Au pair, 27, who dreamed of starting a family is left infertile after battling cervical canceron November 14, 2019 at 12:22 am
An au pair who moved from Canada to the UK in pursuit of a 'fun new life' was dealt a devastating stage III cervical cancer diagnosis just four months later. Brittnay Boomhower, from Toronto, noticed ...
- HPV vaccine the answer to war on cervical canceron November 13, 2019 at 11:00 pm
ALSO READ: No deal on women health rights as ICPD25 summit closes Gavi Deputy Chief Executive Officer Anuradha Gupta said the number of women dying annually from cervical cancer currently stands at ...
- Fundraiser For Cervical Cancer: Musical In Delhi Starring Queen Hitson November 13, 2019 at 7:55 pm
Tickets for the play can be bought here. Proceeds from the tickets for the play, hosted by CAPED (Cancer Awareness, Prevention and Early Detection), will go towards raising funds for cervical cancer, ...
- Contraceptive Drug MPA Shows Promise in Cervical Cancer Preventionon November 13, 2019 at 10:39 am
In mice with precancerous lesions, medroxyprogesterone acetate (MPA) a key ingredient in the common contraceptive injection Depo-Provera was found to be effective in preventing cervical cancer ...
- Microsoft is using its AI power to speed up detection of cervical cancer in Indiaon November 12, 2019 at 6:28 am
Microsoft and SRL Diagnostics' codeveloped AI-enabled tool for detecting cervical cancer can accurately spot abnormalities in cervical sample images.
- Microsoft AI can diagnose cervical cancer and save many lives in Indiaon November 12, 2019 at 3:46 am
A team of researchers has managed to train artificial intelligence to spot cervical cancer in patients, saving doctors an uncountable amount of time. Microsoft and SRL Diagnostics have developed an AI ...
- Contraceptive drug shows promise for preventing and regressing cervical canceron November 12, 2019 at 12:13 am
A new study in The American Journal of Pathology reports that medroxyprogesterone acetate (MPA), the active ingredient in the common contraceptive injection Depo-Provera, was effective in preventing ...
- Microsoft To Use AI Technology To Treat Cervical Cancer In Indiaon November 11, 2019 at 11:21 am
Microsoft is using modern technology to battle cancer, especially in the countries where it is hardest to do so, by using AI technology. Microsoft is currently working with SRL Diagnostics to help the ...
- Microsoft AI helps diagnose cervical cancer fasteron November 10, 2019 at 4:38 pm
It might just be crucial to overloaded doctors in India. In some cases, AI-assisted cancer detection might be more than a convenience -- it could be the key to getting a diagnosis in the first place.
via Bing News